论文部分内容阅读
目的:观察高血压伴2型糖尿病患者采用通心络胶囊综合治疗临床疗效及安全性。方法:按照随机数字表法将本院诊断为高血压伴2型糖尿病的180例患者分组为对照组和治疗组。对照组:采用非洛地平缓释片5 mg,晨起一粒口服,1次/d;格列齐特缓释片30 mg,晨起1粒口服,1次/d。治疗组:对照组治疗基础上加用通心络胶囊,3粒/次,3次/d。观察两组患者治疗前、后血压和血糖、血脂变化及临床疗效、不良反应。结果:治疗前,治疗组SBP和DBP及空腹血糖、餐后2 h血糖分别为(154.98±13.10)mm Hg、(102.10±4.79)mm Hg、(10.12±2.51)nmol/L、(15.98±2.12)nmol/L与对照组(155.12±12.76)mm Hg、(101.75±4.83)mm Hg、(10.15±2.48)nmol/L、(16.02±2.07)nmol/L比较(P>0.05);治疗后,治疗组SBP和DBP及空腹血糖、餐后2 h血糖分别为(117.62±6.94)mm Hg、(78.67±2.39)mm Hg、(6.47±1.39)nmol/L、(11.96±2.01)nmol/L与对照组(129.97±8.79)mm Hg、(95.23±3.61)mm Hg、(6.58±1.41)nmol/L、(12.13±1.96)nmol/L比较,两组患者血压比较(P<0.05);血糖比较(P>0.05)。治疗组治疗有效率与不良反应率分别为92.22%(83/90)、4.44%(4/90)与对照组87.78%(79/90)、12.22%(11/90)比较(P<0.05)。治疗后,两组患者TG与TC、LDL-C水平较治疗前比较均明显下降,而HDL-C较治疗前明显升高,但治疗组改善更明显(P<0.05)。结论:高血压伴2型糖尿病患者采用通心络胶囊综合治疗,其可有效改善患者血糖、血压、血脂等指标,提高临床疗效,且不良反应少,值得推广。
Objective: To observe the clinical efficacy and safety of Tongxinluo capsule in patients with hypertension and type 2 diabetes mellitus. Methods: According to the random number table, 180 patients diagnosed as hypertension with type 2 diabetes in our hospital were divided into control group and treatment group. Control group: the use of felodipine sustained-release tablets 5 mg, early morning one orally, once / d; gliclazide 30 mg, early morning 1 orally, 1 time / d. Treatment group: The control group plus Tongxinluo capsule, 3 capsules / time, 3 times / d. Before and after treatment, blood pressure and blood glucose, blood lipid changes and clinical efficacy, adverse reactions were observed. Results: Before treatment, SBP and DBP, fasting blood glucose and postprandial blood glucose were (154.98 ± 13.10) mm Hg, (102.10 ± 4.79) mm Hg, (10.12 ± 2.51) nmol / L and 15.98 ± 2.12 ) (nmol / L) compared with the control group (155.12 ± 12.76) mmHg, (101.75 ± 4.83) mmHg, (10.15 ± 2.48) nmol / L and (16.02 ± 2.07) nmol / SBP, DBP and fasting blood glucose in the treatment group were (117.62 ± 6.94) mm Hg, (78.67 ± 2.39) mm Hg, (6.47 ± 1.39) nmol / L and (11.96 ± 2.01) nmol / L respectively Compared with the control group (129.97 ± 8.79) mm Hg, (95.23 ± 3.61) mm Hg, (6.58 ± 1.41) nmol / L and (12.13 ± 1.96) nmol / L, (P> 0.05). The effective rate and adverse reaction rate of the treatment group were 92.22% (83/90), 4.44% (4/90) and 87.78% (79/90), 12.22% (11/90) respectively (P <0.05) . After treatment, TG and TC, LDL-C levels in both groups were significantly decreased compared with before treatment, while HDL-C was significantly higher than before treatment, but the treatment group improved more significantly (P <0.05). Conclusion: The combination of Tongxinluo capsule and hypertension patients with type 2 diabetes mellitus can effectively improve the blood glucose, blood pressure, blood lipid and other indicators of patients with type 2 diabetes to improve clinical efficacy and less adverse reactions, which is worth promoting.